Vitamin C Improves Dasatinib Concentrations Under Hypochlorhydric Conditions of the Simulated Stomach Duodenum Model
Purpose pH-dependent drug-drug interactions (DDIs) with poorly soluble, weakly basic drugs may lead to clinical implications. Dasatinib is a tyrosine kinase inhibitor with reduced absorption in patients on acid-reducing agents (ARAs). The objective of this study is to investigate the influence of ga...
Saved in:
| Published in | Pharmaceutical research Vol. 39; no. 9; pp. 2217 - 2226 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
New York
Springer US
01.09.2022
Springer Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0724-8741 1573-904X 1573-904X |
| DOI | 10.1007/s11095-022-03321-y |
Cover
| Abstract | Purpose
pH-dependent drug-drug interactions (DDIs) with poorly soluble, weakly basic drugs may lead to clinical implications. Dasatinib is a tyrosine kinase inhibitor with reduced absorption in patients on acid-reducing agents (ARAs). The objective of this study is to investigate the influence of gastric pH on dasatinib supersaturation and determine if vitamin C (L-ascorbic acid) can improve dasatinib concentrations under simulated hypochlorhydric gastric conditions.
Methods
A dynamic,
in vitro
, multi-compartment, simulated stomach duodenum (SSD) model mimicking fluid volumes and transfer rates was used to investigate the concentration of BCS class IIb drugs versus time curves. Dasatinib and lamotrigine were explored under normal, fasted, simulated gastric fluids (pH 2) (FaSGF), hypochlorhydric simulated gastric fluids (pH 4.5) (FaSGF
hypo
) and FaSGF
hypo
with 1000 mg of vitamin C.
Results
Significant supersaturation of dasatinib was observed in the duodenum compartment of the SSD model in FaSGF. A 90% reduction in dasatinib AUC
∞
was observed in FaSGF
hypo
. Upon addition of vitamin C to FaSGF
hypo
, drug concentrations were restored to those observed in FaSGF. Lamotrigine AUC
∞
in the duodenal compartment were similar in both FaSGF and FaSGF
hypo
. The
in vitro
trends observed for dasatinib and lamotrigine are reflective of the trends observed
in vivo
in subjects receiving treatment with ARAs.
Conclusions
The SSD model serves as a good
in vitro
tool for assessing the effect of pH-dependent DDIs on bioavailability of weakly basic drugs with solubility/ dissolution limited absorption. Vitamin C provides a promising approach for improving bioavailability of poorly soluble, weakly basic drugs in hypochlorhydric patients. |
|---|---|
| AbstractList | PurposepH-dependent drug-drug interactions (DDIs) with poorly soluble, weakly basic drugs may lead to clinical implications. Dasatinib is a tyrosine kinase inhibitor with reduced absorption in patients on acid-reducing agents (ARAs). The objective of this study is to investigate the influence of gastric pH on dasatinib supersaturation and determine if vitamin C (L-ascorbic acid) can improve dasatinib concentrations under simulated hypochlorhydric gastric conditions.MethodsA dynamic, in vitro, multi-compartment, simulated stomach duodenum (SSD) model mimicking fluid volumes and transfer rates was used to investigate the concentration of BCS class IIb drugs versus time curves. Dasatinib and lamotrigine were explored under normal, fasted, simulated gastric fluids (pH 2) (FaSGF), hypochlorhydric simulated gastric fluids (pH 4.5) (FaSGFhypo) and FaSGFhypo with 1000 mg of vitamin C.ResultsSignificant supersaturation of dasatinib was observed in the duodenum compartment of the SSD model in FaSGF. A 90% reduction in dasatinib AUC∞ was observed in FaSGFhypo. Upon addition of vitamin C to FaSGFhypo, drug concentrations were restored to those observed in FaSGF. Lamotrigine AUC∞ in the duodenal compartment were similar in both FaSGF and FaSGFhypo. The in vitro trends observed for dasatinib and lamotrigine are reflective of the trends observed in vivo in subjects receiving treatment with ARAs.ConclusionsThe SSD model serves as a good in vitro tool for assessing the effect of pH-dependent DDIs on bioavailability of weakly basic drugs with solubility/ dissolution limited absorption. Vitamin C provides a promising approach for improving bioavailability of poorly soluble, weakly basic drugs in hypochlorhydric patients. pH-dependent drug-drug interactions (DDIs) with poorly soluble, weakly basic drugs may lead to clinical implications. Dasatinib is a tyrosine kinase inhibitor with reduced absorption in patients on acid-reducing agents (ARAs). The objective of this study is to investigate the influence of gastric pH on dasatinib supersaturation and determine if vitamin C (L-ascorbic acid) can improve dasatinib concentrations under simulated hypochlorhydric gastric conditions.PURPOSEpH-dependent drug-drug interactions (DDIs) with poorly soluble, weakly basic drugs may lead to clinical implications. Dasatinib is a tyrosine kinase inhibitor with reduced absorption in patients on acid-reducing agents (ARAs). The objective of this study is to investigate the influence of gastric pH on dasatinib supersaturation and determine if vitamin C (L-ascorbic acid) can improve dasatinib concentrations under simulated hypochlorhydric gastric conditions.A dynamic, in vitro, multi-compartment, simulated stomach duodenum (SSD) model mimicking fluid volumes and transfer rates was used to investigate the concentration of BCS class IIb drugs versus time curves. Dasatinib and lamotrigine were explored under normal, fasted, simulated gastric fluids (pH 2) (FaSGF), hypochlorhydric simulated gastric fluids (pH 4.5) (FaSGFhypo) and FaSGFhypo with 1000 mg of vitamin C.METHODSA dynamic, in vitro, multi-compartment, simulated stomach duodenum (SSD) model mimicking fluid volumes and transfer rates was used to investigate the concentration of BCS class IIb drugs versus time curves. Dasatinib and lamotrigine were explored under normal, fasted, simulated gastric fluids (pH 2) (FaSGF), hypochlorhydric simulated gastric fluids (pH 4.5) (FaSGFhypo) and FaSGFhypo with 1000 mg of vitamin C.Significant supersaturation of dasatinib was observed in the duodenum compartment of the SSD model in FaSGF. A 90% reduction in dasatinib AUC∞ was observed in FaSGFhypo. Upon addition of vitamin C to FaSGFhypo, drug concentrations were restored to those observed in FaSGF. Lamotrigine AUC∞ in the duodenal compartment were similar in both FaSGF and FaSGFhypo. The in vitro trends observed for dasatinib and lamotrigine are reflective of the trends observed in vivo in subjects receiving treatment with ARAs.RESULTSSignificant supersaturation of dasatinib was observed in the duodenum compartment of the SSD model in FaSGF. A 90% reduction in dasatinib AUC∞ was observed in FaSGFhypo. Upon addition of vitamin C to FaSGFhypo, drug concentrations were restored to those observed in FaSGF. Lamotrigine AUC∞ in the duodenal compartment were similar in both FaSGF and FaSGFhypo. The in vitro trends observed for dasatinib and lamotrigine are reflective of the trends observed in vivo in subjects receiving treatment with ARAs.The SSD model serves as a good in vitro tool for assessing the effect of pH-dependent DDIs on bioavailability of weakly basic drugs with solubility/ dissolution limited absorption. Vitamin C provides a promising approach for improving bioavailability of poorly soluble, weakly basic drugs in hypochlorhydric patients.CONCLUSIONSThe SSD model serves as a good in vitro tool for assessing the effect of pH-dependent DDIs on bioavailability of weakly basic drugs with solubility/ dissolution limited absorption. Vitamin C provides a promising approach for improving bioavailability of poorly soluble, weakly basic drugs in hypochlorhydric patients. pH-dependent drug-drug interactions (DDIs) with poorly soluble, weakly basic drugs may lead to clinical implications. Dasatinib is a tyrosine kinase inhibitor with reduced absorption in patients on acid-reducing agents (ARAs). The objective of this study is to investigate the influence of gastric pH on dasatinib supersaturation and determine if vitamin C (L-ascorbic acid) can improve dasatinib concentrations under simulated hypochlorhydric gastric conditions. A dynamic, in vitro, multi-compartment, simulated stomach duodenum (SSD) model mimicking fluid volumes and transfer rates was used to investigate the concentration of BCS class IIb drugs versus time curves. Dasatinib and lamotrigine were explored under normal, fasted, simulated gastric fluids (pH 2) (FaSGF), hypochlorhydric simulated gastric fluids (pH 4.5) (FaSGF.sub.hypo) and FaSGF.sub.hypo with 1000 mg of vitamin C. Significant supersaturation of dasatinib was observed in the duodenum compartment of the SSD model in FaSGF. A 90% reduction in dasatinib AUC.sub.[infinity] was observed in FaSGF.sub.hypo. Upon addition of vitamin C to FaSGF.sub.hypo, drug concentrations were restored to those observed in FaSGF. Lamotrigine AUC.sub.[infinity] in the duodenal compartment were similar in both FaSGF and FaSGF.sub.hypo. The in vitro trends observed for dasatinib and lamotrigine are reflective of the trends observed in vivo in subjects receiving treatment with ARAs. The SSD model serves as a good in vitro tool for assessing the effect of pH-dependent DDIs on bioavailability of weakly basic drugs with solubility/ dissolution limited absorption. Vitamin C provides a promising approach for improving bioavailability of poorly soluble, weakly basic drugs in hypochlorhydric patients. Purpose pH-dependent drug-drug interactions (DDIs) with poorly soluble, weakly basic drugs may lead to clinical implications. Dasatinib is a tyrosine kinase inhibitor with reduced absorption in patients on acid-reducing agents (ARAs). The objective of this study is to investigate the influence of gastric pH on dasatinib supersaturation and determine if vitamin C (L-ascorbic acid) can improve dasatinib concentrations under simulated hypochlorhydric gastric conditions. Methods A dynamic, in vitro, multi-compartment, simulated stomach duodenum (SSD) model mimicking fluid volumes and transfer rates was used to investigate the concentration of BCS class IIb drugs versus time curves. Dasatinib and lamotrigine were explored under normal, fasted, simulated gastric fluids (pH 2) (FaSGF), hypochlorhydric simulated gastric fluids (pH 4.5) (FaSGF.sub.hypo) and FaSGF.sub.hypo with 1000 mg of vitamin C. Results Significant supersaturation of dasatinib was observed in the duodenum compartment of the SSD model in FaSGF. A 90% reduction in dasatinib AUC.sub.[infinity] was observed in FaSGF.sub.hypo. Upon addition of vitamin C to FaSGF.sub.hypo, drug concentrations were restored to those observed in FaSGF. Lamotrigine AUC.sub.[infinity] in the duodenal compartment were similar in both FaSGF and FaSGF.sub.hypo. The in vitro trends observed for dasatinib and lamotrigine are reflective of the trends observed in vivo in subjects receiving treatment with ARAs. Conclusions The SSD model serves as a good in vitro tool for assessing the effect of pH-dependent DDIs on bioavailability of weakly basic drugs with solubility/ dissolution limited absorption. Vitamin C provides a promising approach for improving bioavailability of poorly soluble, weakly basic drugs in hypochlorhydric patients. Purpose pH-dependent drug-drug interactions (DDIs) with poorly soluble, weakly basic drugs may lead to clinical implications. Dasatinib is a tyrosine kinase inhibitor with reduced absorption in patients on acid-reducing agents (ARAs). The objective of this study is to investigate the influence of gastric pH on dasatinib supersaturation and determine if vitamin C (L-ascorbic acid) can improve dasatinib concentrations under simulated hypochlorhydric gastric conditions. Methods A dynamic, in vitro , multi-compartment, simulated stomach duodenum (SSD) model mimicking fluid volumes and transfer rates was used to investigate the concentration of BCS class IIb drugs versus time curves. Dasatinib and lamotrigine were explored under normal, fasted, simulated gastric fluids (pH 2) (FaSGF), hypochlorhydric simulated gastric fluids (pH 4.5) (FaSGF hypo ) and FaSGF hypo with 1000 mg of vitamin C. Results Significant supersaturation of dasatinib was observed in the duodenum compartment of the SSD model in FaSGF. A 90% reduction in dasatinib AUC ∞ was observed in FaSGF hypo . Upon addition of vitamin C to FaSGF hypo , drug concentrations were restored to those observed in FaSGF. Lamotrigine AUC ∞ in the duodenal compartment were similar in both FaSGF and FaSGF hypo . The in vitro trends observed for dasatinib and lamotrigine are reflective of the trends observed in vivo in subjects receiving treatment with ARAs. Conclusions The SSD model serves as a good in vitro tool for assessing the effect of pH-dependent DDIs on bioavailability of weakly basic drugs with solubility/ dissolution limited absorption. Vitamin C provides a promising approach for improving bioavailability of poorly soluble, weakly basic drugs in hypochlorhydric patients. |
| Audience | Academic |
| Author | Aburub, Aktham Moghrabi, Fouad S. Fadda, Hala M. |
| Author_xml | – sequence: 1 givenname: Fouad S. surname: Moghrabi fullname: Moghrabi, Fouad S. organization: Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Butler University – sequence: 2 givenname: Aktham surname: Aburub fullname: Aburub, Aktham organization: Synthetic Molecule Design and Development, Lilly Research Labs, Eli Lilly & Company – sequence: 3 givenname: Hala M. surname: Fadda fullname: Fadda, Hala M. email: hfadda@butler.edu organization: Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Butler University |
| BookMark | eNp9kU1rFTEUhoNU8Lb6B1wF3LiZevIxNzPLcqu2UHFRK-5Ckkl6U2aSa5IR5t-b6wjFIiWLQ8LzHHLOe4pOQgwWobcEzgmA-JAJgb5tgNIGGKOkWV6gDWkFa3rgP07QBgTlTSc4eYVOc34AgI70fIPKd1_U5APe4evpkOIvm_Glyqr44DXexWBsKKleY8j4Lgw24avlEM1-jGm_DMmbIzT4FYgOl73Ft36aR1XsgG9LnJTZ48s5DjbME_5S6_gavXRqzPbN33qG7j59_La7am6-fr7eXdw0hpO2NJ3SQjurXNtqMJSZXgzEDcS0htJWM22c1gqMFkMd3hLacwWUMNe3xIEBdober33rYD9nm4ucfDZ2HFWwcc6SbjsOvQDOK_ruCfoQ5xTq7yQVlAou2LZ7pO7VaKUPLtbdmGNTeSEo2Ypupc7_Q9Uz2MmbGpzz9f0foVsFk2LOyTppairHlVbRj5KAPKYs15RlTVn-SVkuVaVP1EPyk0rL8xJbpVzhcG_T47DPWL8BS7u9TQ |
| CitedBy_id | crossref_primary_10_1016_j_ijpharm_2022_122069 crossref_primary_10_1021_jacs_3c12502 crossref_primary_10_1016_j_dmpk_2023_100502 |
| Cites_doi | 10.1007/s002280000146 10.1208/s12248-016-9918-x 10.1200/JCO.2015.65.2560 10.1007/s12247-009-9071-5 10.1021/acs.molpharmaceut.5b00154 10.1016/j.xphs.2018.11.005 10.2165/11592630-000000000-00000 10.1093/ajcn/78.5.999 10.1007/BF02088565 10.1016/j.xphs.2018.07.023 10.1021/mp500196f 10.1016/j.ccell.2018.07.014 10.1002/cpt.1569 10.1007/s002280050438 10.1128/AAC.39.8.1671 10.1177/0091270009333854 10.1021/mp400403s 10.1038/clpt.2012.73 10.1016/j.ijpharm.2022.121722 10.1038/clpt.2014.87 10.1177/1533210110392951 10.1080/07315724.2003.10719272 10.1177/1078155217692152 10.1023/a:1018918316253 10.1155/2010/957842 10.1021/acs.molpharmaceut.1c00690 10.1016/j.ijpharm.2011.04.018 10.1208/s12248-014-9673-9 10.1248/bpb.24.313 10.1177/1758835918818347 10.1073/pnas.93.8.3704 10.1007/s00228-008-0576-5 10.1002/cncr.31917 10.3390/nu13020615 |
| ContentType | Journal Article |
| Copyright | The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 COPYRIGHT 2022 Springer The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. |
| Copyright_xml | – notice: The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 – notice: COPYRIGHT 2022 Springer – notice: The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. – notice: 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. |
| DBID | AAYXX CITATION 3V. 7RV 7TK 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.1007/s11095-022-03321-y |
| DatabaseName | CrossRef ProQuest Central (Corporate) Nursing & Allied Health Database Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni) PML(ProQuest Medical Library) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | CrossRef ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest One Academic Middle East (New) MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1573-904X |
| EndPage | 2226 |
| ExternalDocumentID | A721678368 10_1007_s11095_022_03321_y |
| GrantInformation_xml | – fundername: Fulbright Association funderid: http://dx.doi.org/10.13039/100010629 – fundername: Butler University funderid: http://dx.doi.org/10.13039/100006354 |
| GroupedDBID | --- -4W -56 -5G -BR -EM -Y2 -~C .86 .VR 06C 06D 0R~ 0VY 123 199 1N0 1SB 2.D 203 28- 29O 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 3SX 3V. 4.4 406 408 409 40D 40E 53G 5QI 5VS 67N 67Z 6NX 78A 7RV 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYOK AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTHY ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHXU ACIWK ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADYPR ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFDYV AFEXP AFGCZ AFKRA AFLOW AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BKEYQ BPHCQ BSONS BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMOBN EN4 EPAXT ESBYG EX3 F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IAO IHE IHR IJ- IKXTQ IMOTQ INH ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH L7B LAK LLZTM LSO M1P M4Y MA- MK0 N2Q N9A NAPCQ NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI RNS ROL RPX RRX RSV RZC RZE RZK S16 S1Z S26 S27 S28 S3A S3B SAP SBL SBY SCLPG SDH SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZN T13 T16 TEORI TSG TSK TSV TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WH7 WJK WK6 WK8 WOW YCJ YLTOR Z45 Z5O Z7S Z7U Z7V Z7W Z7X Z81 Z82 Z83 Z84 Z87 Z88 Z8N Z8O Z8P Z8Q Z8R Z8V Z8W Z91 Z92 ZGI ZMTXR ZOVNA ~KM AAPKM AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY PUEGO 7TK 7XB 8FK K9. PKEHL PQEST PQUKI PRINS 7X8 |
| ID | FETCH-LOGICAL-c415t-8ab7bfeaf55b0c23c97d1fd1c5c225b3bcfbba0cb7d095e1294a0213f951f0c03 |
| IEDL.DBID | AGYKE |
| ISSN | 0724-8741 1573-904X |
| IngestDate | Thu Sep 04 17:37:41 EDT 2025 Mon Oct 06 17:23:47 EDT 2025 Mon Oct 20 22:18:56 EDT 2025 Mon Oct 20 16:37:46 EDT 2025 Wed Oct 01 04:30:29 EDT 2025 Thu Apr 24 23:07:29 EDT 2025 Fri Feb 21 02:45:31 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | Proton pump inhibitors Oral drug delivery Ionization Dissolution correlations |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c415t-8ab7bfeaf55b0c23c97d1fd1c5c225b3bcfbba0cb7d095e1294a0213f951f0c03 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| PQID | 2722747368 |
| PQPubID | 37334 |
| PageCount | 10 |
| ParticipantIDs | proquest_miscellaneous_2684097044 proquest_journals_2722747368 gale_infotracmisc_A721678368 gale_infotracacademiconefile_A721678368 crossref_citationtrail_10_1007_s11095_022_03321_y crossref_primary_10_1007_s11095_022_03321_y springer_journals_10_1007_s11095_022_03321_y |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-09-01 |
| PublicationDateYYYYMMDD | 2022-09-01 |
| PublicationDate_xml | – month: 09 year: 2022 text: 2022-09-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | New York |
| PublicationPlace_xml | – name: New York |
| PublicationSubtitle | An Official Journal of the American Association of Pharmaceutical Scientists |
| PublicationTitle | Pharmaceutical research |
| PublicationTitleAbbrev | Pharm Res |
| PublicationYear | 2022 |
| Publisher | Springer US Springer Springer Nature B.V |
| Publisher_xml | – name: Springer US – name: Springer – name: Springer Nature B.V |
| References | Zhang, Wu, Lee, Zhao, Zhang (CR2) 2014; 96 Borjian, Ferrari, Anouf, Touyz (CR37) 2010; 2010 van Leeuwen, Peric, Hussaarts, Kienhuis, NS IJ, de Bruijn P (CR32) 2016; 34 Kirchheiner, Glatt, Fuhr, Klotz, Meineke, Seufferlein (CR4) 2009; 65 Sharma, Holmes, Mehta, Chen, Aparasu, Shih (CR40) 2019; 125 CR18 Vaidhyanathan, Wang, Crison, Varia, Gao, Saxena (CR19) 2019; 108 CR38 Morihara, Aoyagi, Kaniwa, Kojima, Ogata (CR10) 2001; 24 Ebert, Thong, Oertel, Kirch (CR17) 2000; 56 Bhattachar, Risley, Werawatganone, Aburub (CR21) 2011; 412 Jaruratanasirikul, Sriwiriyajan (CR8) 1998; 54 Fletcher, Breeze, Shetty (CR29) 2003; 78 Shenoy, Creagan, Witzig, Levine (CR30) 2018; 34 CR31 van Seyen, Colbers, Abbink, Drenth, Burger (CR35) 2019; 106 Budha, Frymoyer, Smelick, Jin, Yago, Dresser (CR1) 2012; 92 Guo, Sun (CR12) 2022; 619 Fish, Young, Shah, Gao (CR22) 2009; 4 Lake-Bakaar, Elsakr, Hagag, Lyubsky, Ahuja, Craddock (CR11) 1996; 41 Knoebel, Larson (CR36) 2018; 24 Levine, Conry-Cantilena, Wang, Welch, Washko, Dhariwal (CR25) 1996; 93 Schlueter, Johnston (CR28) 2011; 16 CR3 Honigford, Aburub, Fadda (CR14) 2019; 108 CR6 Hussaarts, Veerman, Jansman, van Gelder, Mathijssen, van Leeuwen (CR7) 2019; 11 Guo, Sun (CR41) 2022; 19 Smelick, Heffron, Chu, Dean, West, Duvall (CR39) 2013; 10 Nader, Quinney, Fadda, Foster (CR15) 2016; 18 Mitra, Fadda (CR16) 2014; 11 CR27 Vaithianathan, Raman, Jiang, Ting, Kane, Polli (CR20) 2015; 12 CR26 Yago, Frymoyer, Benet, Smelick, Frassetto, Ding (CR23) 2014; 16 CR24 Walravens, Brouwers, Spriet, Tack, Annaert, Augustijns (CR34) 2011; 50 Russell, Berardi, Barnett, O'Sullivan, Wagner, Dressman (CR9) 1994; 11 Padayatty, Katz, Wang, Eck, Kwon, Lee (CR13) 2003; 22 Eley, Luo, Agrawal, Sanil, Manning, Li (CR5) 2009; 49 Chin, Loeb, Fong (CR33) 1995; 39 3321_CR31 L Zhang (3321_CR2) 2014; 96 T Eley (3321_CR5) 2009; 49 S Vaithianathan (3321_CR20) 2015; 12 MR Yago (3321_CR23) 2014; 16 GS Smelick (3321_CR39) 2013; 10 Y Guo (3321_CR41) 2022; 19 K Hussaarts (3321_CR7) 2019; 11 AE Fletcher (3321_CR29) 2003; 78 RW van Leeuwen (3321_CR32) 2016; 34 U Ebert (3321_CR17) 2000; 56 A Borjian (3321_CR37) 2010; 2010 NR Budha (3321_CR1) 2012; 92 N Shenoy (3321_CR30) 2018; 34 M Morihara (3321_CR10) 2001; 24 Y Guo (3321_CR12) 2022; 619 A Mitra (3321_CR16) 2014; 11 AM Nader (3321_CR15) 2016; 18 3321_CR38 3321_CR18 RW Knoebel (3321_CR36) 2018; 24 WP Fish (3321_CR22) 2009; 4 J Walravens (3321_CR34) 2011; 50 SJ Padayatty (3321_CR13) 2003; 22 G Lake-Bakaar (3321_CR11) 1996; 41 AK Schlueter (3321_CR28) 2011; 16 TL Russell (3321_CR9) 1994; 11 SN Bhattachar (3321_CR21) 2011; 412 TW Chin (3321_CR33) 1995; 39 3321_CR6 3321_CR3 M Sharma (3321_CR40) 2019; 125 CR Honigford (3321_CR14) 2019; 108 S Vaidhyanathan (3321_CR19) 2019; 108 S Jaruratanasirikul (3321_CR8) 1998; 54 3321_CR27 M Levine (3321_CR25) 1996; 93 J Kirchheiner (3321_CR4) 2009; 65 3321_CR24 3321_CR26 M van Seyen (3321_CR35) 2019; 106 |
| References_xml | – volume: 56 start-page: 299 issue: 4 year: 2000 end-page: 304 ident: CR17 article-title: Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects publication-title: Eur J Clin Pharmacol doi: 10.1007/s002280000146 – ident: CR18 – volume: 18 start-page: 981 issue: 4 year: 2016 end-page: 988 ident: CR15 article-title: Effect of Gastric Fluid Volume on the Dissolution and Absorption of BCS Class II Drugs: a Case Study with Nifedipine publication-title: AAPS J doi: 10.1208/s12248-016-9918-x – volume: 34 start-page: 1309 issue: 12 year: 2016 end-page: 14 ident: CR32 article-title: Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer publication-title: J Clin Oncol. doi: 10.1200/JCO.2015.65.2560 – volume: 4 start-page: 165 year: 2009 end-page: 173 ident: CR22 article-title: The Use of Experimental Design Principles in Dissolution Method Development: Development of a Discriminating Dissolution Method for Sprycel Film-Coated Tablets publication-title: J Pharm Innov doi: 10.1007/s12247-009-9071-5 – volume: 12 start-page: 2436 issue: 7 year: 2015 end-page: 2443 ident: CR20 article-title: Biopharmaceutic Risk Assessment of Brand and Generic Lamotrigine Tablets publication-title: Mol Pharm doi: 10.1021/acs.molpharmaceut.5b00154 – volume: 108 start-page: 741 issue: 1 year: 2019 end-page: 749 ident: CR19 article-title: Bioequivalence Comparison of Pediatric Dasatinib Formulations and Elucidation of Absorption Mechanisms Through Integrated PBPK Modeling publication-title: J Pharm Sci doi: 10.1016/j.xphs.2018.11.005 – volume: 50 start-page: 725 issue: 11 year: 2011 end-page: 734 ident: CR34 article-title: Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations publication-title: Clin Pharmacokinet doi: 10.2165/11592630-000000000-00000 – volume: 78 start-page: 999 issue: 5 year: 2003 end-page: 1010 ident: CR29 article-title: Antioxidant vitamins and mortality in older persons: findings from the nutrition add-on study to the Medical Research Council Trial of Assessment and Management of Older People in the Community publication-title: Am J Clin Nutr doi: 10.1093/ajcn/78.5.999 – volume: 41 start-page: 1398 issue: 7 year: 1996 end-page: 1408 ident: CR11 article-title: Changes in parietal cell structure and function in HIV disease publication-title: Dig Dis Sci doi: 10.1007/BF02088565 – volume: 108 start-page: 288 issue: 1 year: 2019 end-page: 294 ident: CR14 article-title: A Simulated Stomach Duodenum Model Predicting the Effect of Fluid Volume and Prandial Gastric Flow Patterns on Nifedipine Pharmacokinetics From Cosolvent-Based Capsules publication-title: J Pharm Sci doi: 10.1016/j.xphs.2018.07.023 – volume: 11 start-page: 2835 issue: 8 year: 2014 end-page: 2844 ident: CR16 article-title: Effect of surfactants, gastric emptying, and dosage form on supersaturation of dipyridamole in an model simulating the stomach and duodenum publication-title: Mol Pharm doi: 10.1021/mp500196f – volume: 34 start-page: 700 issue: 5 year: 2018 end-page: 706 ident: CR30 article-title: Ascorbic Acid in Cancer Treatment: Let the Phoenix Fly publication-title: Cancer Cell doi: 10.1016/j.ccell.2018.07.014 – volume: 106 start-page: 1093 issue: 5 year: 2019 end-page: 1098 ident: CR35 article-title: Concomitant Intake of Coca-Cola to Manage the Drug-Drug Interaction Between Velpatasvir and Omeprazole Studied in Healthy Volunteers publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.1569 – ident: CR6 – volume: 54 start-page: 159 issue: 2 year: 1998 end-page: 161 ident: CR8 article-title: Effect of omeprazole on the pharmacokinetics of itraconazole publication-title: Eur J Clin Pharmacol doi: 10.1007/s002280050438 – ident: CR27 – volume: 39 start-page: 1671 issue: 8 year: 1995 end-page: 1675 ident: CR33 article-title: Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.39.8.1671 – volume: 49 start-page: 700 issue: 6 year: 2009 end-page: 709 ident: CR5 article-title: Phase I Study of the Effect of Gastric Acid pH Modulators on the Bioavailability of Oral Dasatinib in Healthy Subjects publication-title: J Clin Pharmacol doi: 10.1177/0091270009333854 – volume: 10 start-page: 4055 issue: 11 year: 2013 end-page: 4062 ident: CR39 article-title: Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development publication-title: Mol Pharm doi: 10.1021/mp400403s – volume: 92 start-page: 203 issue: 2 year: 2012 end-page: 213 ident: CR1 article-title: Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2012.73 – volume: 619 year: 2022 ident: CR12 article-title: Profound effects of gastric secretion rate variations on the precipitation of erlotinib in duodenum - An investigation publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2022.121722 – volume: 96 start-page: 266 issue: 2 year: 2014 end-page: 277 ident: CR2 article-title: pH-Dependent Drug-Drug Interactions for Weak Base Drugs: Potential Implications for New Drug Development publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2014.87 – volume: 16 start-page: 49 issue: 1 year: 2011 end-page: 57 ident: CR28 article-title: Vitamin C: Overview and update publication-title: Journal of Evidence-Based Complementary and Alternative Medicine doi: 10.1177/1533210110392951 – volume: 22 start-page: 18 issue: 1 year: 2003 end-page: 35 ident: CR13 article-title: Vitamin C as an antioxidant: evaluation of its role in disease prevention publication-title: J Am Coll Nutr doi: 10.1080/07315724.2003.10719272 – ident: CR3 – volume: 24 start-page: 156 issue: 2 year: 2018 end-page: 158 ident: CR36 article-title: Pepsi(R) or Coke(R)? Influence of acid on dasatinib absorption publication-title: J Oncol Pharm Pract doi: 10.1177/1078155217692152 – ident: CR38 – volume: 11 start-page: 136 issue: 1 year: 1994 end-page: 143 ident: CR9 article-title: pH-related changes in the absorption of dipyridamole in the elderly publication-title: Pharm Res doi: 10.1023/a:1018918316253 – ident: CR31 – volume: 2010 year: 2010 ident: CR37 article-title: Pop-cola acids and tooth erosion: an , , electron-microscopic, and clinical report publication-title: Int J Dent doi: 10.1155/2010/957842 – volume: 19 start-page: 432 issue: 2 year: 2022 end-page: 439 ident: CR41 article-title: Pharmaceutical Lauryl Sulfate Salts: Prevalence, Formation Rules, and Formulation Implications publication-title: Mol Pharm doi: 10.1021/acs.molpharmaceut.1c00690 – volume: 412 start-page: 95 issue: 1–2 year: 2011 end-page: 98 ident: CR21 article-title: Weak bases and formation of a less soluble lauryl sulfate salt/complex in sodium lauryl sulfate (SLS) containing media publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2011.04.018 – volume: 16 start-page: 1358 issue: 6 year: 2014 end-page: 1365 ident: CR23 article-title: The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria publication-title: AAPS J doi: 10.1208/s12248-014-9673-9 – volume: 24 start-page: 313 issue: 3 year: 2001 end-page: 315 ident: CR10 article-title: Assessment of gastric acidity of Japanese subjects over the last 15 years publication-title: Biol Pharm Bull doi: 10.1248/bpb.24.313 – volume: 11 start-page: 1758835918818347 year: 2019 ident: CR7 article-title: Clinically relevant drug interactions with multikinase inhibitors: a review publication-title: Ther Adv Med Oncol doi: 10.1177/1758835918818347 – ident: CR26 – ident: CR24 – volume: 93 start-page: 3704 issue: 8 year: 1996 end-page: 3709 ident: CR25 article-title: Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.93.8.3704 – volume: 65 start-page: 19 issue: 1 year: 2009 end-page: 31 ident: CR4 article-title: Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-008-0576-5 – volume: 125 start-page: 1155 issue: 7 year: 2019 end-page: 1162 ident: CR40 article-title: The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer publication-title: Cancer doi: 10.1002/cncr.31917 – ident: 3321_CR26 – volume: 18 start-page: 981 issue: 4 year: 2016 ident: 3321_CR15 publication-title: AAPS J doi: 10.1208/s12248-016-9918-x – volume: 56 start-page: 299 issue: 4 year: 2000 ident: 3321_CR17 publication-title: Eur J Clin Pharmacol doi: 10.1007/s002280000146 – volume: 54 start-page: 159 issue: 2 year: 1998 ident: 3321_CR8 publication-title: Eur J Clin Pharmacol doi: 10.1007/s002280050438 – volume: 16 start-page: 49 issue: 1 year: 2011 ident: 3321_CR28 publication-title: Journal of Evidence-Based Complementary and Alternative Medicine doi: 10.1177/1533210110392951 – ident: 3321_CR24 – volume: 96 start-page: 266 issue: 2 year: 2014 ident: 3321_CR2 publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2014.87 – volume: 108 start-page: 741 issue: 1 year: 2019 ident: 3321_CR19 publication-title: J Pharm Sci doi: 10.1016/j.xphs.2018.11.005 – volume: 92 start-page: 203 issue: 2 year: 2012 ident: 3321_CR1 publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2012.73 – ident: 3321_CR18 – volume: 4 start-page: 165 year: 2009 ident: 3321_CR22 publication-title: J Pharm Innov doi: 10.1007/s12247-009-9071-5 – volume: 10 start-page: 4055 issue: 11 year: 2013 ident: 3321_CR39 publication-title: Mol Pharm doi: 10.1021/mp400403s – volume: 11 start-page: 2835 issue: 8 year: 2014 ident: 3321_CR16 publication-title: Mol Pharm doi: 10.1021/mp500196f – volume: 49 start-page: 700 issue: 6 year: 2009 ident: 3321_CR5 publication-title: J Clin Pharmacol doi: 10.1177/0091270009333854 – volume: 2010 year: 2010 ident: 3321_CR37 publication-title: Int J Dent doi: 10.1155/2010/957842 – ident: 3321_CR38 – volume: 125 start-page: 1155 issue: 7 year: 2019 ident: 3321_CR40 publication-title: Cancer doi: 10.1002/cncr.31917 – ident: 3321_CR6 – volume: 619 year: 2022 ident: 3321_CR12 publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2022.121722 – volume: 93 start-page: 3704 issue: 8 year: 1996 ident: 3321_CR25 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.93.8.3704 – volume: 65 start-page: 19 issue: 1 year: 2009 ident: 3321_CR4 publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-008-0576-5 – volume: 34 start-page: 700 issue: 5 year: 2018 ident: 3321_CR30 publication-title: Cancer Cell doi: 10.1016/j.ccell.2018.07.014 – volume: 16 start-page: 1358 issue: 6 year: 2014 ident: 3321_CR23 publication-title: AAPS J doi: 10.1208/s12248-014-9673-9 – volume: 34 start-page: 1309 issue: 12 year: 2016 ident: 3321_CR32 publication-title: J Clin Oncol. doi: 10.1200/JCO.2015.65.2560 – ident: 3321_CR27 – volume: 106 start-page: 1093 issue: 5 year: 2019 ident: 3321_CR35 publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.1569 – volume: 108 start-page: 288 issue: 1 year: 2019 ident: 3321_CR14 publication-title: J Pharm Sci doi: 10.1016/j.xphs.2018.07.023 – volume: 11 start-page: 136 issue: 1 year: 1994 ident: 3321_CR9 publication-title: Pharm Res doi: 10.1023/a:1018918316253 – volume: 50 start-page: 725 issue: 11 year: 2011 ident: 3321_CR34 publication-title: Clin Pharmacokinet doi: 10.2165/11592630-000000000-00000 – volume: 24 start-page: 156 issue: 2 year: 2018 ident: 3321_CR36 publication-title: J Oncol Pharm Pract doi: 10.1177/1078155217692152 – volume: 11 start-page: 175883591881834 year: 2019 ident: 3321_CR7 publication-title: Ther Adv Med Oncol doi: 10.1177/1758835918818347 – volume: 41 start-page: 1398 issue: 7 year: 1996 ident: 3321_CR11 publication-title: Dig Dis Sci doi: 10.1007/BF02088565 – volume: 12 start-page: 2436 issue: 7 year: 2015 ident: 3321_CR20 publication-title: Mol Pharm doi: 10.1021/acs.molpharmaceut.5b00154 – volume: 19 start-page: 432 issue: 2 year: 2022 ident: 3321_CR41 publication-title: Mol Pharm doi: 10.1021/acs.molpharmaceut.1c00690 – volume: 412 start-page: 95 issue: 1–2 year: 2011 ident: 3321_CR21 publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2011.04.018 – volume: 78 start-page: 999 issue: 5 year: 2003 ident: 3321_CR29 publication-title: Am J Clin Nutr doi: 10.1093/ajcn/78.5.999 – ident: 3321_CR31 doi: 10.3390/nu13020615 – ident: 3321_CR3 – volume: 24 start-page: 313 issue: 3 year: 2001 ident: 3321_CR10 publication-title: Biol Pharm Bull doi: 10.1248/bpb.24.313 – volume: 39 start-page: 1671 issue: 8 year: 1995 ident: 3321_CR33 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.39.8.1671 – volume: 22 start-page: 18 issue: 1 year: 2003 ident: 3321_CR13 publication-title: J Am Coll Nutr doi: 10.1080/07315724.2003.10719272 |
| SSID | ssj0008194 |
| Score | 2.4138446 |
| Snippet | Purpose
pH-dependent drug-drug interactions (DDIs) with poorly soluble, weakly basic drugs may lead to clinical implications. Dasatinib is a tyrosine kinase... Purpose pH-dependent drug-drug interactions (DDIs) with poorly soluble, weakly basic drugs may lead to clinical implications. Dasatinib is a tyrosine kinase... pH-dependent drug-drug interactions (DDIs) with poorly soluble, weakly basic drugs may lead to clinical implications. Dasatinib is a tyrosine kinase inhibitor... PurposepH-dependent drug-drug interactions (DDIs) with poorly soluble, weakly basic drugs may lead to clinical implications. Dasatinib is a tyrosine kinase... |
| SourceID | proquest gale crossref springer |
| SourceType | Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 2217 |
| SubjectTerms | Ascorbic acid Bioavailability Biochemistry Biomedical and Life Sciences Biomedical Engineering and Bioengineering Biomedicine Dasatinib Drugs Duodenum Enzyme inhibitors Football (College) Lamotrigine Medical Law Original Research Article Patients pH effects Pharmacology/Toxicology Pharmacy Protein-tyrosine kinase Reducing agents Small intestine Trends Tyrosine Vitamin C |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LaxsxEBapc-mlpC-6bVpUKOmhFpW02tehlNRJMIUa0yQlt0WPXWxIdp14fdh_n5l9eHFDctYTzWg0kub7hpAvSgcuDkPH8LeRKadClsTOssQFoQ4jLmyO75B_ZuH0Uv2-Cq72yKzHwmBYZW8TG0PtSotv5N9lJPEC5Yfxz9Utw6xR-Lvap9DQXWoF96OhGHtG9iUyY43I_q_T2fzv1jbD-dcQSkVSgR1QooPRtGA6wRu0smTc96Vg9c5R9b_BfvBz2hxIZwfkRedJ0uNW9C_JXla8Ikfzloq6HtOLAVm1HtMjOh9IquvXpPq3rPTNsqAT2r4rZGt6ojG0p1gaOkEwY9Ex6q5pkxyJTutVaRdwv1_UDqwnVnJtwBctcwqOJD1f3mA2sMzR86qEsRb0ZFM6DLanmHPt-g25PDu9mExZl4GBWTjYKxZrE5k803kQGG6lb5PIidwJG1iwA8Y3NjdGc2siB2uXge-gNDgNfg5-W84t99-SUVEW2TtCeWQ1uAtSci2U0cI47WKeOATmxi4QHhH9Yqe2oyfHLBnX6UCsjAJKQUBpI6C09si3bZtVS87xZO2vKMMUdy70bHUHQID5IQdWeow8RghqiT1yuFMTdpzdLe61IO12_Dod9NMjn7fF2BKj2Iqs3EAdZNZJIq6UR8a99gxdPD7190-P-IE8l43eYujbIRlVd5vsI_hKlfnUbYB7XJUQzg priority: 102 providerName: ProQuest |
| Title | Vitamin C Improves Dasatinib Concentrations Under Hypochlorhydric Conditions of the Simulated Stomach Duodenum Model |
| URI | https://link.springer.com/article/10.1007/s11095-022-03321-y https://www.proquest.com/docview/2722747368 https://www.proquest.com/docview/2684097044 |
| Volume | 39 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVLSH databaseName: SpringerLink Journals customDbUrl: mediaType: online eissn: 1573-904X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0008194 issn: 0724-8741 databaseCode: AFBBN dateStart: 19970101 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVAVX databaseName: SpringerLINK - Czech Republic Consortium customDbUrl: eissn: 1573-904X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0008194 issn: 0724-8741 databaseCode: AGYKE dateStart: 19970101 isFulltext: true titleUrlDefault: http://link.springer.com providerName: Springer Nature – providerCode: PRVAVX databaseName: SpringerLink Journals (ICM) customDbUrl: eissn: 1573-904X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0008194 issn: 0724-8741 databaseCode: U2A dateStart: 19970101 isFulltext: true titleUrlDefault: http://www.springerlink.com/journals/ providerName: Springer Nature |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9swDBbW9LLL1r2wbF2gAUN3WFzI8kP2MUmTBRsWBGszZCdDDxsJltpF7RzcXz_SjwTpHkBPPoiSZZmkCInfR0I-uNIzge8bC28bLde4vhUGRluh8XzpC2brBM8hv8386cL9svSWDSgsb7Pd2yvJylPvwW42q9DE3GKOw22rPCLHFd9WhxwPPv_8Ot55YNjlKtoowV2wdtduwDJ_H-VgQ7rvlv-4H622nclTsmgnXGeb_DrfFupc393jcnzoF52QJ00cSge14jwjj-L0OTmb10TWZZ9e7XFZeZ-e0fme4rp8QYof60Jer1M6ovWpRJzTC4mJQela0RFCIdOGjzenVWklOi1vMr3aZLer0oDvRSFTp4vRLKEQhtLL9TXWEosNvSwyeNeKXmwzg6n6FCu2bV6SxWR8NZpaTf0GS0NYUFiBVEIlsUw8TzHNHR0KYyfG1p4GL6IcpROlJNNKGFiHGCIPV0LI4SQQ9SVMM-cV6aRZGr8mlAktIdjgnEnbVdJWRpqAhQZhvYHx7C6x258Y6YbcHGtsbKI9LTMudgSLHVWLHZVd8mnX56am9viv9EfUjQjtHkbWsoEvwPyQQSsaIAsSQmKCLjk9kAR71YfNrXZFjb_IIy44Hg9Uze93zdgTc-DSONuCDPLyhIK5bpf0W4XaD_Hvqb95mPhb8phXOomJdKekU9xu43cQeRWqR47EUvTA3CbD4azXmB08h-PZ_Du0LvjgN3T3Kbk |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6V9gAXxFMYCiwSlAOxul6vX4cKlaRVStsooinqzezDViKldqgdIf85fhszfiQKiN569r7kmZ2Z3Z3vG0LeC-mZ0PeNja-NtjDCt6PQaDsyni_9gDk6xXvI85E_vBRfr7yrLfK7w8JgWmVnE2tDbXKNd-T7POB4gHL98PPip41Vo_B1tSuhIdvSCuagphhrgR2nSfULjnDFwckA5P2B8-OjSX9ot1UGbA3Oq7RDqQKVJjL1PMU0d3UUGCc1jvY06LpylU6VkkyrwEA4koB_FBIco5tCbJIyzVwY9x7ZEa6I4PC38-VoNP628gXgb2sCq4ALsDvCaWE7DXjPYTU6mtvMdbljVxuu8W8H8c9Lbe0Ajx-Rh23kSg8bVXtMtpLsCdkbN9TXVY9O1kiuokf36HhNil09JeX3WSmvZxnt0-YeIynoQGIqUTZTtI_gyaxl8C1oXYyJDqtFrqfz_GZaGbDW2Mg0CWY0TykErvRido3VxxJDL8oc5prSwTI3mNxPscbb_Bm5vBNZPCfbWZ4lLwhlgZYQnnDOpCOUdJSRJmSRQSBwaDzHIk73s2Pd0qFjVY55vCZyRgHFIKC4FlBcWeTTqs-iIQO5tfVHlGGMlgJG1rIFPMD6kHMrPkTeJATRhBbZ3WgJO1xvfu60IG4tTBGv94NF3q0-Y0_MmsuSfAltkMknCpgQFul12rMe4v9Lf3n7jG_J_eHk_Cw-OxmdviIPeK3DmHa3S7bLm2XyGuK0Ur1pNwMlP-56__0B1GNPeg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGkBAviKsIG2AkGA80muNcnDwgNLVUHYOp0jbUt8yXRK3UJd2SCuWv8es4J5dGBbG3Pcexo5yr7fN9h5D3nvRNGATGxttG2zNeYEeh0XZk_EAGgjk6xXPIH6fB5ML7NvNnO-R3h4XBssrOJ9aO2uQaz8gPueC4gXKD8DBtyyKmo_GX1bWNHaTwprVrp9GoyElS_YLtW_H5eASy_sD5-Ov5cGK3HQZsDYGrtEOphEoTmfq-Ypq7OhLGSY2jfQ16rlylU6Uk00oYSEUSiI2ehKDoppCXpEwzF-a9R-4L142wnFDMNps9jLQ1dZXgHngcz2kBOw1sz2E1LprbzHW5Y1dbQfHv0PDPHW0d-saPyaM2Z6VHjZI9ITtJ9pQcTBvS62pAz3sMVzGgB3Ta02FXz0j5c1HKq0VGh7Q5wUgKOpJYRJQtFB0ibDJruXsLWrdhopNqlev5Mr-ZVwb8NA4yTWkZzVMKKSs9W1xh37HE0LMyh7XmdLTODZb1U-zutnxOLu5EEi_IbpZnyUtCmdASEhPOmXQ8JR1lpAlZZBACHBrfsYjT_exYt0To2I9jGfcUziigGAQU1wKKK4t82ryzamhAbh39EWUYo4-AmbVsoQ7wfci2FR8hYxLCZ0KL7G-NBNvW2487LYhb31LEvSVY5N3mMb6J9XJZkq9hDHL4RIJ5nkUGnfb0U_z_01_dvuJb8gCsLv5-fHqyRx7yWoWx3m6f7JY36-Q1JGilelNbAiWXd216fwClyE0U |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Vitamin+C+Improves+Dasatinib+Concentrations+Under+Hypochlorhydric+Conditions+of+the+Simulated+Stomach+Duodenum+Model&rft.jtitle=Pharmaceutical+research&rft.au=Moghrabi%2C+Fouad+S.&rft.au=Aburub%2C+Aktham&rft.au=Fadda%2C+Hala+M.&rft.date=2022-09-01&rft.pub=Springer+US&rft.issn=0724-8741&rft.eissn=1573-904X&rft.volume=39&rft.issue=9&rft.spage=2217&rft.epage=2226&rft_id=info:doi/10.1007%2Fs11095-022-03321-y&rft.externalDocID=10_1007_s11095_022_03321_y |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0724-8741&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0724-8741&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0724-8741&client=summon |